Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN
Debiopharm Group (Lausanne, Switzerland) completed enrollment of 96 patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) in the Phase II portion of a double-blind, placebo-controlled, French and Swiss Phase I/II trial of oral Debio 1143 (AT-406) in combination with chemo-radiation therapy (CRT). Debio 1143 is a small molecule inhibitor of apoptosis (IAP).
The trial is evaluating Debio 1143 daily...
Read the full 307 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Week In Review
Article Purchase
$35 USD
